small molecule

AUBAGIO

TERIFLUNOMIDE

Loss of exclusivityAugust 2034latest FDA-listed patent expiry
CompanySANOFI AVENTIS US LLC

Drug detail

Brand nameAUBAGIO
Active ingredientTERIFLUNOMIDE
Strength7MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2012
Marketing statusRX

Listed patents

PatentExpiresType
9186346*PEDAugust 2034
9186346February 2034use U-1786
8802735*PEDMarch 2031
8802735September 2030product
6794410*PEDMarch 2027
6794410September 2026use U-1285

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

AUBAGIO patent cliff — loss of exclusivity August 2034 | CliffBio